Page Banner

United States Department of Agriculture

Agricultural Research Service


item Cray, Paula
item Haro, Jovita
item Rose, Marcus

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 4/16/2006
Publication Date: 5/16/2006
Citation: Cray, P.J., Haro, J.H., Rose, M. 2006. In-vitro susceptibility of bovine salmonella enterica to cefquinome and cefepime. Third International Conference on Antimicrobial Agents in Veterinary Medicine (AAVM). p 33.

Interpretive Summary:

Technical Abstract: Background: The purpose of this study was to monitor the in-vitro susceptibility of bovine Salmonella enterica, isolated in the US, against the 4th generation cephalosporins (4-GC) cefquinome and cefepime. Cefquinome is licensed for therapeutic use in cattle and swine in Europe, and cefepime is licensed for therapeutic use in human medicine (The Sanford Guide, 2005). Methods: Salmonella enterica isolates (n=3,985) obtained from cattle at federally inspected slaughter/processing plants during 2000 - 2004 and submitted to the animal arm of the National Antimicrobial Resistance Monitoring System – Enteric Bacteria (NARMS) were tested for minimum inhibitory concentrations (MICs) using a custom panel of antimicrobials, and a second panel with cefquinome and cefepime (CLSI, 2002). Results: The MIC50 of the 4-GC cefquinome and cefepime against all bovine Salmonella enterica isolates remained at 0.06 µg/ml throughout the 5-year period, except during 2002 when cefquinome activity increased by one dilution to 0.12 µg/ml. The MIC90 for both cefquinome and cefepime was 0.12 µg/ml in 2000, which increased to 1.0 µg/ml and 0.5 µg/ml, respectively, for 2002, and decreased to 0.5 µg/ml and 0.25 µg/ml for cefquinome and cefepime, respectively, in 2003 and 2004. Most common serotypes throughout this period were S. Montevideo, S. Newport, and S. Anatum, with MICs differing among serotypes. Conclusions: Salmonella enterica isolates remained highly susceptible to the veterinary 4-GC cefquinome and the human 4-GC cefepime over the 5-year observation period. Both drugs have high antimicrobial activity with MICs far below the cefepime resistance breakpoint of > 32 µg/ml (CLSI, 2003)

Last Modified: 10/20/2017
Footer Content Back to Top of Page